Advanced Search

Study Preview



Study Title and Description

Efficacy and safety of chitosan HEP-40 in the management of hypercholesterolemia: a randomized, multicenter, placebo-controlled trial.



Key Questions Addressed
1 Is this an intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Efficacy and safety of chitosan HEP-40 in the management of hypercholesterolemia: a randomized, multicenter, placebo-controlled trial.
Author Jaffer S., Sampalis JS.
Country Internal Medicine, Delta Hospital, Delta, British Columbia, Canada.
Year 2007
Numbers Pubmed ID: 18072822

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber 4.1
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
pubyear 2007
  • Comments Comments (
    0
    ) |
country Canada
  • Comments Comments (
    0
    ) |
design Randomized Controlled Trial (parallel)
  • Comments Comments (
    0
    ) |
blindness Double blind
  • Comments Comments (
    0
    ) |
diet NCEP Step 1 Diet regimen
  • Comments Comments (
    0
    ) |
feedcontrol Subjects all continued on NCEP Step 1 Diet regimen, and they were provided with supplements
  • Comments Comments (
    0
    ) |
sampsize 105
  • Comments Comments (
    0
    ) |
runin No
  • Comments Comments (
    0
    ) |
washout Not applicable
  • Comments Comments (
    0
    ) |
dosechange No
  • Comments Comments (
    0
    ) |
age_adult 1
  • Comments Comments (
    0
    ) |
age_adol
  • Comments Comments (
    0
    ) |
age_child
  • Comments Comments (
    0
    ) |
age_baby
  • Comments Comments (
    0
    ) |
age_infant
  • Comments Comments (
    0
    ) |
age_oth
  • Comments Comments (
    0
    ) |
age_mean 53
  • Comments Comments (
    0
    ) |
age_range 29-76
  • Comments Comments (
    0
    ) |
bmi_mean 29.4
  • Comments Comments (
    0
    ) |
bmi_range
  • Comments Comments (
    0
    ) |
blhealth_healthy
  • Comments Comments (
    0
    ) |
blhealth_hyperlip 1
  • Comments Comments (
    0
    ) |
blhealth_diab
  • Comments Comments (
    0
    ) |
blhealth_hyperten
  • Comments Comments (
    0
    ) |
blhealth_digest
  • Comments Comments (
    0
    ) |
blhealth_met
  • Comments Comments (
    0
    ) |
blhealth_oth
  • Comments Comments (
    0
    ) |
blhealth_othspec
  • Comments Comments (
    0
    ) |
gender 62.3
  • Comments Comments (
    0
    ) |
ftype1 Chitosan
  • Comments Comments (
    0
    ) |
descrip1_1
  • Comments Comments (
    0
    ) |
descrip1_2
  • Comments Comments (
    0
    ) |
dose1_1 1.2
  • Comments Comments (
    0
    ) |
dose1_2
  • Comments Comments (
    0
    ) |
duration1 12 weeks
  • Comments Comments (
    0
    ) |
admin1 Tablet
  • Comments Comments (
    0
    ) |
ftype2 Chitosan
  • Comments Comments (
    0
    ) |
descrip2_1
  • Comments Comments (
    0
    ) |
descrip2_2
  • Comments Comments (
    0
    ) |
dose2_1 1.6
  • Comments Comments (
    0
    ) |
dose2_2
  • Comments Comments (
    0
    ) |
duration2 12 weeks
  • Comments Comments (
    0
    ) |
admin2 Tablet
  • Comments Comments (
    0
    ) |
ftype3 Chitosan
  • Comments Comments (
    0
    ) |
descrip3_1
  • Comments Comments (
    0
    ) |
descrip3_2
  • Comments Comments (
    0
    ) |
dose3_1 2.4
  • Comments Comments (
    0
    ) |
dose3_2
  • Comments Comments (
    0
    ) |
duration3 12 weeks
  • Comments Comments (
    0
    ) |
admin3 Tablet
  • Comments Comments (
    0
    ) |
ftype4 Chitosan
  • Comments Comments (
    0
    ) |
descrip4_1
  • Comments Comments (
    0
    ) |
descrip4_2
  • Comments Comments (
    0
    ) |
dose4_1 2.4
  • Comments Comments (
    0
    ) |
dose4_2
  • Comments Comments (
    0
    ) |
duration4 12 weeks
  • Comments Comments (
    0
    ) |
admin4 Tablet
  • Comments Comments (
    0
    ) |
comparator1 Placebo, microcrystalline cellulose (no chitosan)
  • Comments Comments (
    0
    ) |
cdose1 0
  • Comments Comments (
    0
    ) |
cduration1 12 weeks
  • Comments Comments (
    0
    ) |
cadmin1 Tablet
  • Comments Comments (
    0
    ) |
comparator2
  • Comments Comments (
    0
    ) |
cdose2
  • Comments Comments (
    0
    ) |
cduration2
  • Comments Comments (
    0
    ) |
cadmin2
  • Comments Comments (
    0
    ) |
comparator3
  • Comments Comments (
    0
    ) |
cdose3
  • Comments Comments (
    0
    ) |
cduration3
  • Comments Comments (
    0
    ) |
cadmin3
  • Comments Comments (
    0
    ) |
comparator4
  • Comments Comments (
    0
    ) |
cdose4
  • Comments Comments (
    0
    ) |
cduration4
  • Comments Comments (
    0
    ) |
cadmin4
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.